Latest Innovations in LC/MS/MS from Waters for Metabolism and Bioanalytical Applications Ignatius J. Kass Senior Field Marketing Manager Pharmaceutical MS
Challenges in Pharmaceutical Sample Analysis Quantitative Bioanalysis Robust reliable methods Sensitivity Analyte confirmation Matrix effects Metabolites In Safety Testing Obtain qualitative data? Metabolic Profiling Confidence Sensitivity Throughput Obtain quantitative data?
New Additions to the Xevo Family Class leading UPLC MS and MS/MS performance Technology for simultaneous targeted quantification and high-sensitivity full scan MS and MS/MS monitoring The most sensitive, exact-mass, quantitative and qualitative benchtop MS/MS system Uses UPLC/MS E, a simple, patented method of data acquisition to comprehensively catalog complex samples in a single analysis
Analytical Workflow Engineered Simplicity Prepare IntelliStart technology for simplified set-up Analyze Enhanced compatibility with ACQUITY UPLC Performance and usability through Engineered Simplicity TM Automated calibration check and system monitoring Outstanding instrument sensitivity and selectivity Interpret MassLynx application managers, utilizing chemical intelligence, make sense of large, complex data sets Decide Arrive at business / research critical information faster
Intellistart IntelliStart Automated MS Resolution & Calibration Checks Performance and usability through Engineered Simplicity TM IntelliStart Automated MRM Method Developer Quanpedia Automated MRM Time Window & Data Rate Scheduling IntelliStart Automated LC/MS System Check Automatically ensure the system is ready to run IntelliStart Automated System Monitoring.
Innovations Providing Solutions for Quantitative Bioanalysis Radar Faster method development Qualitative profiling capability Step Wave Increased sensitivity Tools to assist with Regulatory Guidelines Matrix Factor determination MIST Guidelines
Method Development: More Depth to Your Data 0.97 1.95 0 Fluticasone 501>293 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 1 Fluticasone 501>293 0.50 1.00 1.50 2.00 2.50 3.00 1.08 1.61 Radar Solvent Blank Radar Solvent Blank 2.19 2.32 2.79 4 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 0.83 1.17 1.29 Radar Plasma Blank 4 0.50 1.00 1.50 2.00 2.50 3.00 Radar Plasma Blank 1.65 2.36 1 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 1 0.50 1.00 1.50 2.00 2.50 3.00 0 Phospholipids 184>184 1.00 1.17 1.27 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 1.56 1.79 1.97 2.23 Time0 Phospholipids 184>184 2.29 2.60 2.96 2.78 0.50 1.00 1.50 2.00 2.50 3.00 Time
Calculating a Spiked Simple MethodMatrix Factor XIC Analyte XIC Internal Standard Solvent + Analyte and Internal Standard Extracted Matrix + Analyte and Internal Standard A= 100 A= 90 A= 95 A= 85 MF = A matrix /A solvent MF = 90/100 =.90 MF = A matrix /A solvent MF = 85/95 =.89 IS Normalized MF = MF AN /MF IS IS Normalized MF =.90/.89 = 1.01
Alternate Approach for Calculating Matrix Factors LC Column MRM Signal 1) Determine AnalyteProfile AN and IS injected through the column 2) Inject Solvent Blank 3) Inject Extracted Matrix Blank Solvent Blank injected with post column infusion of AN and IS Extracted Blank injected with post column infusion of AN and IS AN and IS infused post-column Analyte = AN Internal Standard = IS
Automating Matrix Factor Calculations: Integrated Intellistart Fluidics
Matrix Factor Calculation Results 1 0.40 0.60 0.80 1.00 1.20 1.40 Time 1 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 Time
Quantitative Bioanalysis: Pushing the Sensitivity Barriers Potent, low dose compounds Biologics and Therapeutic peptides challenge the sensitivity requirements: Multiple charge states Many fragments Desmopressin
Desmopressin 25x S:N Xevo TQ-S Xevo TQ
StepWave, Radar and ScanWave Enabled Analysis: More Information Ibuprofen - MRM Glucuronide Metabolite Full Scan MS Hydroxyl - Glucuronide Metabolite - Full Scan MS Ketone Metabolite - Full Scan MS
ScanWave Enhanced Product Ion Spectra Ibuprofen MRM ScanWave Collision Cell Enhanced product ion spectra Ketone Metabolite Glucuronide Metabolite Hydroxyl Glucuronide Metabolite
An alternate Approach to Full Scan Profiling Metabolites Screen for selected panel of metabolites Commonly reported metabolites User definable Predicts metabolite MRMs based upon Parent Compound MSMS Generates MANY MRMs 1 msec dwell With RADAR, full scan MS may be added to the experiment
Develop Theoretical MRMs to Investigate MSMS of Parent Compound Identify Product Ions From Parent Compound Select Metabolites from list of probable transformations MS Source and Analyzer Conditions Automatic Product Ion Selection Spectra of Parent Automatically Obtained from MassLynx Calculate MRMs and Write MS Method File imrm Method List of Potential Metabolites from Text File
imrm method
Compare Full Scan vs MRM Experiment Full Scan MS 100-900 MRM Group 6 32 3 hr 17_4_005a 100 0 17_4_005a 100 0 17_4_005a 100 XIC 416.15 Group 6 32 3 hr 12: MS2 ES+ 3.15 416.148 1.01e6 0.50 1.00 1.50 2.00 2.50 3.00 12: MS2 ES+ 2.69 458.195 2.77e5 XIC 458.19 2.45 2.93 3.21 2.06 0.50 1.00 1.50 2.00 2.50 3.00 12: MS2 ES+ 2.93 428.184 3.18 4.40e5 XIC 428.18 2.70 2.88 0 3 Dealkylation 1.96 0.50 1.00 1.50 2.00 2.50 3.00 3.50 1.48 Hydroxylation 1.97 3.16 0.50 1.00 1.50 2.00 2.50 3.00 3.50 Demethylation 1.84 MRM 416.15>325.85 MRM 458.20>339.85 MRM 428.18>325.83 0 17_4_005a 100 0.50 1.00 1.50 2.00 2.50 3.00 12: MS2 ES+ 2.11 442.2 3.15e6 XIC 442.2 2.92 0 0.50 1.00 1.50 2.00 2.50 3.00 3.50 Parent 2.11 MRM 442.2>325.85 0 0.50 1.00 1.50 2.00 2.50 3.00 Time 0 Time 0.50 1.00 1.50 2.00 2.50 3.00 3.50
m/z 428 -Demethylation 1.84 MRM 416.14>325.85 PIC Scan Acquisition 0.50 1.00 1.50 2.00 2.50 3.00 100 0 100 326 3.93e5 3.17 2.93 326 Full Scan MS 100-900 XIC 416.14 313 0 2.43 2.71 0.50 1.00 1.50 2.00 2.50 3.00 258 298 313 0 m/z 100 125 150 175 200 225 250 275 300 325 350 375 400 425 312 340 341 364 411
Metabolic Stability Plots 300 250 200 150 100 50 0 Demethylation 1 2 3 4 5 6 7 8 80 70 60 50 40 30 20 10 0 Hydroxylation 1.48 1.97 2.06 2.12
Latest innovations in Metabolite Profiling Xevo G2 QTof Intellistart Maximizes instrument uptime and ensures optimal performance and consistency From Lab to Lab and user to user QuanTof MS E Quantitative information in addition to full high resolution scan accurate mass profiling Structural analysis for metabolite localization
Metabolite Identification WorkFlow For in-vitro/in-vivo samples Resolve metabolites chromatographically UPLC strategy for sensitivity and resolution Detect metabolites UPLC/MS, MS E Exact mass, Data rich information Eliminate background and control peaks Identify metabolites MetaboLynx for data processing Identification of expected and unexpected metabolites Mass defect filtering Confirm metabolite structures MassFragment for metabolite structure assignment and confirmation Quantify metabolites Absolute or relative quantification of metabolites
Alternate Scanning LC-MS (LC-MS E ) time resolved accurate mass measurements LE LE m1 sec EE D. EE Gas cell collision energy alternates between MS E low (typically, 5 ev) and is a UNBIASED process elevated energy (typically,5 ev linear ramp from 15 ev - 42 ev) LC-MS E alternate scanning provides quantitative accurate mass measurement for all detectable peptide precursor and product ions throughout UPLC separation EE EE
MetaboLynx XS: 1 µm Human Liver Microsome Verapamil Incubation Samples Found Metabolites Combined Metabolites MS Spectrum Metabolite XIC of Metabolite XIC of Metabolite in Control Parent Drug Structure
MSMS Information Displayed in the Fragment Analysis Window. Product Ion Information Precursor Ion Information Neutral Loss Information
Verapamil Product Ion Spectrum Interpretation Ver0319_002 1179 (8.845) 165.0916 100 2: TOF MS ES+ 4.15e5 455.2909 303.2072 456.2942 166.0948 150.0680 260.1651 304.2098 261.1644 105.0699 133.0646 457.2968 177.0913185.0778 305.2119 239.0966 0 m/z 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460
MassFragment Structural Assignment
Verapamil Fragment Assignment to Structure Ver0319_002 1179 (8.845) 165.0916 100-0.0.mDa 2: TOF MS ES+ 4.15e5-0.1 mda -0.1 mda -0.5mDa -0.1mDa -0.0 mda 303.2072 455.2909 456.2942 166.0948 150.0680 260.1651 304.2098 261.1644 105.0699 133.0646 457.2968 177.0913185.0778 305.2119 239.0966 0 m/z 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460
Samples, Time Course
Metabolic Stability Plot
Alprazolam Quantitation Curve QuanTof Fully TargetLynx Compatible Alprazolam in PPT Plasma 3x Dev <20 at LOQ Dev <15 other
Alprazolam Quantitation Curve Absolute, Internal Standards: R 2 = 0.9989 R 2 =0.9989 20 pg/ml 20 pg/ml to 200 ng/ml 200,000 pg/ml Relative Response Factors: Via Orthogonal Detection (UV, RAD)
Summary Xevo TQ-S and Xevo G2 QTof provide class leading instrument performance Innovative Technologies such as StepWave, ScanWave and QuanTof engineered to integrate into existing workflows and open paths to new workflows for comprehensive sample analysis and increased productivity LCMS Innovations to merge Quantitative and Qualitative analysis without compromising your analytical objectives
Acknowledgements Waters Corporation Paul Rainville Marian Twohig Joanne Mather Rob Plumb Kate Yu Henry Shion Steve McDonald Gordon Fujumoto Alan Millar Jeff Goshawk Alex Hooper Hoffman-LaRoche Zhenmin Liang Astra Zeneca, UK David Higton Dotmatics, LTD